Press Releases

 BOSTON, MA – November 20, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today positive 12 month follow up data from its CGuardTM CARENET (CARotid Embolic protection Study using microNET) trial at the 42nd Annual Symposium on Vascular… Read More

BOSTON, MA – November 10, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the third quarter ended September 30, 2015. In its third full quarter of a strategic transition into the… Read More

BOSTON, MA – November 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it will release its full financial results for the third quarter ended September 30, 2015 on Tuesday, November 10th before the market open,… Read More

CGuardTM Clinical Data Presented at TCT 2015 Carotid Scientific Sessions   BOSTON, MA – October 19, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commercialize the CGuardTM Embolic Prevention System… Read More

BOSTON, MA – September 8, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that Chief Executive Officer, Alan Milinazzo, will present at the Dawson James Securities Growth Stock Conference on October 15, 2015.  The presentation will take… Read More

BOSTON, MA – October 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commercialize the CGuardTM Embolic Prevention System for the treatment of carotid artery disease in Colombia. The approval… Read More

BOSTON, MA – October 1, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today a one-for-ten reverse split of its common stock, effective as of 12:00 am Eastern Time on October 1, 2015.  Beginning with the opening of… Read More

BOSTON, MA – September 28, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today the full market launch of the CGuardTM Embolic Prevention System for the treatment of carotid artery disease by its strategic distribution partner, Penumbra, Inc…. Read More

Continued Focus on Intellectual Property Results in Continued Portfolio Expansion BOSTON, MA – September 17, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has issued two new patents to… Read More

Continues to Strengthen and Broaden Intellectual Property Portfolio   BOSTON, MA – September 9, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has allowed claims for its United States… Read More